The phase 2 clinical trial for the anti-tau medication donanemab, which aims to prevent the accumulation of tau tangles, failed in August 2024; fosgonimeton, which aims to improve brain function by focusing on neurotrophic pathways, failed in September 2024; and dalzanemdor, which was tested on patients with mild cognitive impairment and early-stage dementia, failed to demonstrate any discernible improvement in AD and was discontinued in October 2024. The gene discussed is MAPT; the disease is Alzheimer disease.